11/25
09:08 am
imrx
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
imrx
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
11/15
01:42 am
imrx
11/13
09:01 am
imrx
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Medium
Report
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
11/12
09:14 pm
imrx
Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:05 pm
imrx
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
Low
Report
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
11/11
05:42 pm
imrx
Immuneering Q3 2025 Earnings Preview [Seeking Alpha]
Low
Report
Immuneering Q3 2025 Earnings Preview [Seeking Alpha]
11/4
04:05 pm
imrx
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
Low
Report
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
11/1
06:55 am
imrx
Immuneering (NASDAQ:IMRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Immuneering (NASDAQ:IMRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/31
08:06 am
imrx
Immuneering (NASDAQ:IMRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $15.00 price target on the stock.
Medium
Report
Immuneering (NASDAQ:IMRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $15.00 price target on the stock.
10/29
09:03 am
imrx
Immuneering (NASDAQ:IMRX) was given a new $12.00 price target on by analysts at Mizuho.
Medium
Report
Immuneering (NASDAQ:IMRX) was given a new $12.00 price target on by analysts at Mizuho.
10/12
03:39 pm
imrx
SA Asks: What's the most attractive biotech stock right now? [Seeking Alpha]
Low
Report
SA Asks: What's the most attractive biotech stock right now? [Seeking Alpha]
10/8
12:25 pm
imrx
Immuneering (NASDAQ:IMRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immuneering (NASDAQ:IMRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
10:21 am
imrx
OS endpoint focus will realign industry to “ultimate goal” [Yahoo! Finance]
Medium
Report
OS endpoint focus will realign industry to “ultimate goal” [Yahoo! Finance]
9/30
12:00 pm
imrx
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) [Yahoo! Finance]
Medium
Report
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) [Yahoo! Finance]
9/30
08:05 am
imrx
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Medium
Report
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
9/29
09:59 pm
imrx
Immuneering Corporation (IMRX) Discusses Phase 2a Data Update For IMM-1-104 In First-Line Pancreatic Cancer (Transcript) [Seeking Alpha]
Medium
Report
Immuneering Corporation (IMRX) Discusses Phase 2a Data Update For IMM-1-104 In First-Line Pancreatic Cancer (Transcript) [Seeking Alpha]
9/29
04:38 pm
imrx
Immuneering Corporation - Special Call [Seeking Alpha]
Medium
Report
Immuneering Corporation - Special Call [Seeking Alpha]
9/26
04:23 pm
imrx
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 [Yahoo! Finance]
High
Report
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 [Yahoo! Finance]
9/26
04:01 pm
imrx
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
High
Report
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
9/26
08:05 am
imrx
Immuneering (NASDAQ:IMRX) had its price target raised by analysts at Chardan Capital from $13.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Immuneering (NASDAQ:IMRX) had its price target raised by analysts at Chardan Capital from $13.00 to $20.00. They now have a "buy" rating on the stock.
9/25
02:20 pm
imrx
Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst [Seeking Alpha]
Medium
Report
Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst [Seeking Alpha]
9/25
10:00 am
imrx
Immuneering (NASDAQ:IMRX) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $21.00 to $30.00. They now have an "outperform" rating on the stock.
Medium
Report
Immuneering (NASDAQ:IMRX) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $21.00 to $30.00. They now have an "outperform" rating on the stock.
9/25
05:03 am
imrx
Biggest stock movers Thursday: RIG, IMRX, and more [Seeking Alpha]
High
Report
Biggest stock movers Thursday: RIG, IMRX, and more [Seeking Alpha]
9/25
12:24 am
imrx
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi [Yahoo! Finance]
High
Report
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi [Yahoo! Finance]